2022
Multicenter analysis of stereotactic radiosurgery for multiple brain metastases from EGFR and ALK driven non-small cell lung cancer
Wandrey N, Gao D, Robin T, Contessa J, Singh C, Chiang V, Li J, Chen A, Wang Y, Sheehan J, Dutta S, Weiss S, Paly J, Rusthoven C. Multicenter analysis of stereotactic radiosurgery for multiple brain metastases from EGFR and ALK driven non-small cell lung cancer. Lung Cancer 2022, 176: 144-148. PMID: 36641932, PMCID: PMC10552603, DOI: 10.1016/j.lungcan.2022.11.019.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerOverall survivalCell lung cancerStereotactic radiosurgeryBrain metastasesMultivariable adjustmentMulticenter analysisLung cancerNext-generation tyrosine kinase inhibitorsSRS treatmentOnly negative prognostic factorWhole brain radiotherapyMedian overall survivalMultiple brain metastasesNegative prognostic factorFavorable overall survivalTyrosine kinase inhibitorsTreatment 1CNS progressionMulticenter outcomesMedian followPrognostic factorsFavorable prognosisCNS diseaseTreatment optionsEfficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
de Groot JF, Kim AH, Prabhu S, Rao G, Laxton AW, Fecci PE, O’Brien B, Sloan A, Chiang V, Tatter SB, Mohammadi AM, Placantonakis DG, Strowd RE, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D, Sinicrope KD, Campian JL, Kurz SC, Williams B, Smith K, Tovar-Spinoza Z, Leuthardt EC. Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. Neuro-Oncology Advances 2022, 4: vdac040. PMID: 35611270, PMCID: PMC9122789, DOI: 10.1093/noajnl/vdac040.Peer-Reviewed Original ResearchMedian overall survivalLaser interstitial thermal therapyOverall survivalRecurrent patientsWild-type glioblastomaRecurrent glioblastomaGlioblastoma patientsProspective multicenter registry dataMulticenter registry dataRecurrent glioblastoma patientsChemo/radiationPrimary brain tumorsInterstitial thermal therapyIDH wild-type glioblastomaAdjuvant chemotherapyAdverse eventsImproved survivalClinical outcomesPromoter methylation statusMultivariable differenceSurgical approachTreatment optionsRegistry dataUS CentersTumor volume
2021
SURG-02. Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (SRS) as a treatment strategy for brain metastasis that recurred locally after initial radiosurgery (BMRS): a collaborative institutional experience
Pena-Pino I, Ma J, Hori Y, Fomchenko E, Dusenbery K, Reynolds M, Wilke C, Yuan J, Barnett G, Chiang V, Mohammadi A, Chen C. SURG-02. Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (SRS) as a treatment strategy for brain metastasis that recurred locally after initial radiosurgery (BMRS): a collaborative institutional experience. Neuro-Oncology Advances 2021, 3: iii23-iii23. PMCID: PMC8351296, DOI: 10.1093/noajnl/vdab071.095.Peer-Reviewed Original ResearchStereotactic laser ablationStereotactic radiosurgeryOverall survivalTreatment strategiesLocal controlDays of SRSSymptomatic radiation necrosisMedian overall survivalSystemic disease progressionRepeat stereotactic radiosurgeryIndependent clinical trialsInitial radiosurgerySteroid therapyBrain metastasesClinical outcomesRadiation necrosisFavorable outcomeClinical trialsDisease progressionFLAIR volumeInstitutional experiencePatientsCE volumeRadiosurgeryLocal failureOutcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases
Uezono H, Nam D, Kluger HM, Sznol M, Hurwitz M, Yu JB, Chiang VL. Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases. American Journal Of Clinical Oncology 2021, 44: 495-501. PMID: 34432667, DOI: 10.1097/coc.0000000000000849.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsRCC brain metastasesBrain metastasesRenal cell carcinomaStereotactic radiosurgeryOverall survivalUse of ICIsCentral nervous system toxicityRenal cell carcinoma patientsImpact of immunotherapyLocal control outcomesMedian overall survivalCell carcinoma patientsKaplan-Meier curvesNervous system toxicityBetter median OSLog-rank testMann-Whitney U testMargin doseMedian OSNonimmunotherapy groupSRS doseCheckpoint inhibitorsImmunotherapy groupCarcinoma patients
2020
Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases
Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T, Yomo S, Aiyama H, Higuchi Y, Shuto T, Akabane A, Sato Y, Niranjan A, Faramand AM, Lunsford LD, McInerney J, Tuanquin LC, Zacharia BE, Chiang V, Singh C, Yu JB, Braunstein S, Mathieu D, Touchette CJ, Lee CC, Yang HC, Aizer AA, Cagney DN, Chan MD, Kondziolka D, Bernstein K, Silverman JS, Grills IS, Siddiqui ZA, Yuan JC, Sheehan JP, Cordeiro D, Nosaki K, Seto T, Deibert CP, Verma V, Day S, Halasz LM, Warnick RE, Trifiletti DM, Palmer JD, Attia A, Li B, Cifarelli CP, Brown PD, Vargo JA, Combs SE, Kessel KA, Rieken S, Patel S, Guckenberger M, Andratschke N, Kavanagh BD, Robin TP. Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. JAMA Oncology 2020, 6: 1028-1037. PMID: 32496550, PMCID: PMC7273318, DOI: 10.1001/jamaoncol.2020.1271.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyProgression-free survivalSmall-cell lung cancer (SCLC) brain metastasesCell lung cancer brain metastasesCNS progression-free survivalLung cancer brain metastasesPropensity score-matched analysisMedian overall survivalCancer brain metastasesBrain metastasesOverall survivalStereotactic radiosurgeryCentral nervous system (CNS) progression-free survivalMedian CNS progression-free survivalSRS outcomesCentral nervous system progressionSmall cell lung cancerLimited brain metastasesMulticenter cohort studyDisease control statusCell lung cancerSingle-arm trialStandard of careLeptomeningeal progressionWBRT cohortMulti-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy.
Miccio JA, Barsky A, Gao S, Verma V, Noticewala SS, Jairam V, Johnson SB, Yu JB, Hansen JE, Aneja S, An Y, Decker RH, Bulent Omay S, Li J, Kurtz GA, Alonso-Basanta M, Lee JYK, Chiang VL, Park HS. Multi-institutional retrospective review of stereotactic radiosurgery for brain metastasis in patients with small cell lung cancer without prior brain-directed radiotherapy. Journal Of Radiosurgery And SBRT 2020, 7: 19-27. PMID: 32802575, PMCID: PMC7406345.Peer-Reviewed Original ResearchWhole brain radiotherapyBrain metastasesOverall survivalNeurologic deathSmall-cell lung cancer (SCLC) brain metastasesCell lung cancer brain metastasesLung cancer brain metastasesSalvage whole brain radiotherapyMulti-institutional retrospective reviewSmall cell lung cancerMost SCLC patientsSCLC brain metastasesTime of SRSMedian overall survivalCancer brain metastasesCell lung cancerIntracranial progressionSCLC patientsUpfront radiosurgeryBrain radiationBrain radiotherapySelect patientsRetrospective reviewLung cancerStereotactic radiosurgery
2019
Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery
McTyre ER, Soike MH, Farris M, Ayala-Peacock DN, Hepel JT, Page BR, Shen C, Kleinberg L, Contessa JN, Corso C, Chiang V, Henson-Masters A, Cramer CK, Ruiz J, Pasche B, Watabe K, D'Agostino R, Su J, Laxton AW, Tatter SB, Fiveash JB, Ahluwalia M, Kotecha R, Chao ST, Braunstein SE, Attia A, Chung C, Chan MD. Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery. Radiotherapy And Oncology 2019, 142: 168-174. PMID: 31526671, DOI: 10.1016/j.radonc.2019.08.011.Peer-Reviewed Original ResearchConceptsBrain metastasis velocityDistant brain failureMedian overall survivalOverall survivalBrain metastasesPredictors of OSInitial brain metastasesNew brain metastasesWhole brain radiationKaplan-Meier methodHigh-risk groupPredictors of outcomeProportional hazards methodsMulti-institutional settingMulti-institutional validationMultivariate regression modelingInitial SRSBrain radiationSalvage modalityInitial treatmentBrain failureRecurrence rateValidation cohortBMV groupMelanoma histologyBrain Metastasis From Renal-Cell Carcinoma: An Institutional Study
Suarez-Sarmiento A, Nguyen KA, Syed JS, Nolte A, Ghabili K, Cheng M, Liu S, Chiang V, Kluger H, Hurwitz M, Shuch B. Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study. Clinical Genitourinary Cancer 2019, 17: e1163-e1170. PMID: 31519468, DOI: 10.1016/j.clgc.2019.08.006.Peer-Reviewed Original ResearchConceptsRCC brain metastasesRecurrence-free survivalRenal cell carcinomaBrain metastasesOverall survivalClinical trialsAdvanced renal cell carcinomaCentral nervous system treatmentClear cell renal cell carcinomaMedian overall survivalSingle institution experienceGood local controlKaplan-Meier methodAggressive therapyCNS recurrenceTreatment eraCumulative incidenceExtracranial metastasesMetastatic diseaseSystemic therapyInitial presentationLocal therapyClinical symptomsRCC patientsCell carcinomaRADI-34. USE OF LOW-DOSE STEREOTACTIC RADIOSURGERY FOR ADVANCED BRAIN METASTASES
Yang D, Yu J, Chiang V. RADI-34. USE OF LOW-DOSE STEREOTACTIC RADIOSURGERY FOR ADVANCED BRAIN METASTASES. Neuro-Oncology Advances 2019, 1: i28-i28. PMCID: PMC7213353, DOI: 10.1093/noajnl/vdz014.126.Peer-Reviewed Original ResearchGamma Knife stereotactic radiosurgeryBrain metastasesStereotactic radiosurgeryOverall survivalDisease progressionTime to disease progressionBRAF V600E tumorsMutation-targeted therapiesMedian overall survivalMetastatic melanoma patientsTreat brain metastasesPoor performance statusTumor controlMelanoma patientsSystemic therapyAdvanced diseasePerformance statusRe-treatmentTesticular cancerComposite endpointMetastasisSystemic agentsStudy exitImmunotherapyPatientsRADI-31. MULTI-INSTITUTIONAL VALIDATION OF BRAIN METASTASIS VELOCITY, A RECENTLY DEFINED PREDICTOR OF OUTCOMES FOLLOWING STEREOTACTIC RADIOSURGERY
Chan M, McTyre E, Soike M, Ayala-Peacock D, Hepel J, Page B, Contessa J, Chiang V, Attia A, Braunstein S, Chung C, Ruiz J, Fiveash J, Chao S, Farris M. RADI-31. MULTI-INSTITUTIONAL VALIDATION OF BRAIN METASTASIS VELOCITY, A RECENTLY DEFINED PREDICTOR OF OUTCOMES FOLLOWING STEREOTACTIC RADIOSURGERY. Neuro-Oncology Advances 2019, 1: i28-i28. PMCID: PMC7213264, DOI: 10.1093/noajnl/vdz014.123.Peer-Reviewed Original ResearchBrain metastasis velocityDistant brain failureMedian overall survivalOverall survivalPredictors of OSNew brain metastasesImproved overall survivalWhole brain radiationKaplan-Meier methodHigh-risk groupPredictors of outcomeProportional hazards methodsMulti-institutional settingMulti-institutional validationInitial salvageInitial SRSBrain metastasesBrain radiationSalvage modalityInitial treatmentRecurrence rateValidation cohortBrain failureBMV groupHazards methodsInitial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience
Hughes RT, Masters AH, McTyre ER, Farris MK, Chung C, Page BR, Kleinberg LR, Hepel J, Contessa JN, Chiang V, Ruiz J, Watabe K, Su J, Fiveash JB, Braunstein S, Chao S, Attia A, Ayala-Peacock DN, Chan MD. Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience. International Journal Of Radiation Oncology • Biology • Physics 2019, 104: 1091-1098. PMID: 30959122, DOI: 10.1016/j.ijrobp.2019.03.052.Peer-Reviewed Original ResearchConceptsDistant brain failureInitial stereotactic radiosurgerySalvage whole brain radiation therapyWhole-brain radiation therapySalvage stereotactic radiosurgeryBrain metastasesBrain radiation therapyOverall survivalStereotactic radiosurgeryBM groupCumulative incidenceRadiation therapyNumber of BMTwo-year cumulative incidenceMultivariable Cox proportional hazardsBrain metastasis velocityMedian overall survivalOutcomes of patientsKaplan-Meier methodLog-rank testMulti-institutional experienceRisk regression modelingCox proportional hazardsMultivariable analysisNew metastases
2018
SURG-06. LASER ABLATION FOR BRAIN METASTASES: SAFETY AND PRELIMINARY OUTCOMES FROM THE LASER ABLATION OF ABNORMAL NEUROLOGICAL TISSUE USING ROBOTIC NEUROBLATE SYSTEM (LAANTERN) REGISTRY
Kamath A, Tatter S, Fecci P, Chen C, Chiang V, Rao G, Mohammadi A, Judy K, Field M, Neimat J, Leuthardt E, Kim A. SURG-06. LASER ABLATION FOR BRAIN METASTASES: SAFETY AND PRELIMINARY OUTCOMES FROM THE LASER ABLATION OF ABNORMAL NEUROLOGICAL TISSUE USING ROBOTIC NEUROBLATE SYSTEM (LAANTERN) REGISTRY. Neuro-Oncology 2018, 20: vi251-vi251. PMCID: PMC6216263, DOI: 10.1093/neuonc/noy148.1042.Peer-Reviewed Original ResearchLaser interstitial thermal therapyBrain metastasesProcedural dataDeath rateAblation coverageMedian overall survivalAcceptable safety profileSingle-center experienceDay of procedureKaplan-Meier survivalNeurological tissuesAverage lesion volumeLocation of lesionsPreliminary outcomesInterstitial thermal therapyAdverse eventsOngoing registryOverall survivalCenter experienceSafety profileMean ageInvasive optionTarget lesionsProcedural efficacyLesion volume
2017
SURG-21. LASER ABLATION IN STEREOTACTIC NEUROSURGERY (LAISE): A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS OF LITT FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMAS (GBMS)
Sloan A, Tatter S, Mohammadi A, Judy K, Prabhu S, Lovick D, Chamoun R, Chiang V, Leuthardt E. SURG-21. LASER ABLATION IN STEREOTACTIC NEUROSURGERY (LAISE): A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS OF LITT FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMAS (GBMS). Neuro-Oncology 2017, 19: vi239-vi240. PMCID: PMC5693007, DOI: 10.1093/neuonc/nox168.977.Peer-Reviewed Original ResearchRecurrent GBMLaser interstitial thermotherapyRecurrent glioblastomaMulti-institutional retrospective analysisMedian ICU stayMedian overall survivalMedian patient ageTime of diagnosisLarger median volumeECOG statusICU stayConsecutive patientsOverall survivalPatient ageUnresectable tumorsRetrospective seriesMale genderTotal stayMedian volumeRetrospective analysisInvasive proceduresOutcome differencesBrain tumorsNewly DiagnosedPatients
2016
Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases
Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2016, 95: 673-679. PMID: 27034176, DOI: 10.1016/j.ijrobp.2016.01.037.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyUpfront EGFR-TKIIntracranial progression-free survivalUpfront radiation therapyProgression-free survivalBrain metastasesEGFR-TKI groupEGFR-TKIEGFR-mutant NSCLCOverall survivalRadiation therapyEpidermal Growth Factor Receptor–Mutant NonDisease-specific Graded Prognostic AssessmentUpfront EGFR tyrosine kinase inhibitorsEGFR-TKI resistance mutationSmall cell lung cancerEGFR tyrosine kinase inhibitorsEGFR-TKI useMedian overall survivalSimilar overall survivalUpfront RT groupInferior overall survivalCell lung cancerMutant lung adenocarcinomaEpidermal growth factor receptor
2015
Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?
Colaco RJ, Martin P, Kluger HM, Yu JB, Chiang VL. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? Journal Of Neurosurgery 2015, 125: 17-23. PMID: 26544782, DOI: 10.3171/2015.6.jns142763.Peer-Reviewed Original ResearchConceptsTreatment-related imaging changesCytotoxic chemotherapyRadiation necrosisBrain metastasesSystemic therapyStereotactic Gamma Knife radiosurgeryMedian overall survivalGamma knife radiosurgeryHigh-dose radiationChemotherapy eraGK surgeryImmunotherapy increasesMedian followConclusions PatientsOverall survivalImaging changesGK treatmentKnife radiosurgeryInflammatory reactionStereotactic radiosurgeryLower riskRadiosurgical treatmentPatientsImmunotherapyTherapy
2013
Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery
Raldow AC, Chiang VL, Knisely JP, Yu JB. Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery. American Journal Of Clinical Oncology 2013, 36: 486-490. PMID: 22706180, DOI: 10.1097/coc.0b013e31825494ef.Peer-Reviewed Original ResearchConceptsKarnofsky performance statusMore brain metastasesMedian overall survivalOverall survivalBrain metastasesRecurrence-free survivalStereotactic radiosurgeryWhole-brain radiation treatmentGamma Knife stereotactic radiosurgeryNumber of metastasesProportional hazards regressionGamma knife treatmentIntracranial controlOnly significant variableFree survivalIntracranial failurePerformance statusHazards regressionSurveillance imagingHistorical controlsDisease progressionRetrospective analysisPatientsFirst treatmentMetastasis